Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: The Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study

被引:15
|
作者
Engelberger, Rolf P. [1 ,2 ,3 ]
Noll, Georg [4 ]
Schmidt, Dominique
Alatri, Adriano [1 ]
Frei, Benedikt
Kaiser, Walter E. [5 ]
Kucher, Nils [2 ,3 ,6 ]
机构
[1] CHU Vaudois, Div Angiol, CH-1011 Lausanne, Switzerland
[2] Inselspital Bern, Univ Hosp, Swiss Cardiovasc Ctr, Clin Angiol, Bern, Switzerland
[3] Univ Bern, CH-3012 Bern, Switzerland
[4] Klin Hirslanden, HerzKlin, Zurich, Switzerland
[5] DocWorld AG, Menzingen, Switzerland
[6] Univ Hosp, Inselspital, Swiss Cardiovasc Ctr, Clin Cardiol, Bern, Switzerland
关键词
Atrial fibrillation; Primary care; Rivaroxaban; Stroke prevention; Treatment satisfaction; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; TREATMENT SATISFACTION; ORAL ANTICOAGULATION; WARFARIN; RISK; DABIGATRAN; ADHERENCE; MANAGEMENT; PHYSICIANS;
D O I
10.1016/j.ejim.2015.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rivaroxaban has become an alternative to vitamin-K antagonists (VKA) for stroke prevention in non-valvular atrial fibrillation (AF) patients due to its favourable risk-benefit profile in the restrictive setting of a large randomized trial. However in the primary care setting, physician's motivation to begin with rivaroxaban, treatment satisfaction and the clinical event rate after the initiation of rivaroxaban are not known. Methods: Prospective data collection by 115 primary care physicians in Switzerland on consecutive nonvalvular AF patients with newly established rivaroxaban anticoagulation with 3-month follow-up. Results: We enrolled 537 patients (73 +/- 11 years, 57% men) with mean CHADS2 and HAS-BLED-scores of 2.2 +/- 1.3 and 2.4 +/- 1.1, respectively: 301(56%) were switched from VKA to rivaroxaban (STR-group) and 236(44%) were VKA-naive (VN-group). Absence of routine coagulation monitoring (68%) and fixed-dose once-daily treatment (58%) were the most frequent criteria for physicians to initiate rivaroxaban. In the STR-group, patient's satisfaction increased from 3.6 +/- 1.4 under VKA to 5.5 +/- 0.8 points (P < 0.001), and overall physician satisfaction from 3.9 +/- 1.3 to 5.4 +/- 0.9 points (P < 0.001) at 3months of rivaroxaban therapy (score from 1 to 6 with higher scores indicating greater satisfaction). In the VN-group, both patient's (5.4 +/- 0.9) and physician's satisfaction (5.5 +/- 0.7) at follow-up were comparable to the STR-group. During follow-up, 1(0.19%; 95% CI, 0.01-1.03%) ischemic stroke, 2(0.37%; 95% CI, 0.05-1.34%) major non-fatal bleeding and 11(2.05%; 95% CI, 1.03-3.64%) minor bleeding complications occurred. Rivaroxaban was stopped in 30(5.6%) patients, with side effects being the most frequent reason. Conclusion: Initiation of rivaroxaban for patients with nonvalvular AF by primary care physicians was associated with a low clinical event rate and with high overall patient's and physician's satisfaction. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:508 / 514
页数:7
相关论文
共 50 条
  • [21] Antithrombotic Therapy in Nonvalvular Atrial Fibrillation
    Hochtl, T.
    Huber, K.
    JOURNAL FUR KARDIOLOGIE, 2013, 20 (5-6): : 154 - 159
  • [22] Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
    Noseworthy, Peter A.
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    McBane, Robert D.
    Shah, Nilay D.
    CHEST, 2016, 150 (06) : 1302 - 1312
  • [23] Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Review
    Krasner, Andrew
    Halperin, Jonathan L.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (07)
  • [24] A real-world study of different doses of rivaroxaban in patients with nonvalvular atrial fibrillation
    Yan, Xinsheng
    Zhang, Litao
    Zhang, Dan
    Wang, Xiaosu
    MEDICINE, 2024, 103 (17) : E38053
  • [25] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [26] Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation
    Te, Abigail Louise D.
    Chao, Tze-Fan
    Chen, Shih-Ann
    CURRENT CARDIOVASCULAR RISK REPORTS, 2019, 13 (02)
  • [27] Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
    Silva, Vanessa M.
    Scanavacca, Mauricio
    Darrieux, Francisco
    Cavalheiro, Cyrillo
    Strunz, Celia C.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [28] Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
    Jaksa, Ashley
    Gibbs, Liza
    Kent, Seamus
    Rowark, Shaun
    Duffield, Stephen
    Sharma, Manuj
    Kincaid, Lynne
    Ali, Ayad K.
    Patrick, Amanda R.
    Govil, Priya
    Jonsson, Pall
    Gatto, Nicolle
    BMJ OPEN, 2022, 12 (10):
  • [29] Oral Anticoagulant Discontinuation in Patients With Nonvalvular Atrial Fibrillation
    Kachroo, Sumesh
    Hamilton, Melissa
    Liu, Xianchen
    Pan, Xianying
    Brixner, Diana
    Marrouche, Nassir
    Biskupiak, Joseph
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (01): : E1 - E8
  • [30] Trough Concentration Deficiency of Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation Leading to Thromboembolism Events
    Gao, Hongjin
    Li, Yumei
    Sun, Hong
    Huang, Xiufang
    Chen, Hui
    Lin, Wei
    Chen, Min
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 80 (06) : 869 - 876